Advertisement

Annals of Hematology

, 88:1199 | Cite as

Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome

  • Antonia BusseEmail author
  • Nicola Gökbuget
  • Jan Michael Siehl
  • Dieter Hoelzer
  • Stefan Schwartz
  • Anika Rietz
  • Eckhard Thiel
  • Ulrich Keilholz
Original Article

Abstract

Wilms’ tumor gene 1 (WT1) is gaining increasing attention as a therapeutic target molecule due to its common expression in acute leukemias and its involvement in cell proliferation. Here, we reported on WT1 messenger RNA expression levels at diagnosis in a series of 238 adult acute lymphoblastic leukemia (ALL) samples of various subtypes and clinical outcome. WT1 expression was found in 219 out of 238 ALL samples (92%). Compared to a cohort of acute myeloid leukemia patients, the median WT1 expression level in ALL was significantly lower with large variations among different ALL subgroups. Specifically, WT1 expression levels were low in mature B-ALL and highest in ALL cases with co-expression of myeloid markers, making it a useful therapeutic target molecule in adult ALL with the exception of mature B-ALL. Cox regression analysis, considering ALL phenotype as well as molecular-cytogenetic subsets, revealed no independent prognostic role of WT1 expression level for disease-free and overall survival.

Keywords

Adult ALL WT1 

Notes

Acknowledgement

We want to thank Alberto Fusi for critical reading the manuscript.

References

  1. 1.
    Haber DA, Housman DE (1992) Role of the WT1 gene in Wilms’ tumour. Cancer Surv 12:105–117PubMedGoogle Scholar
  2. 2.
    Hohenstein P, Hastie ND (2006) The many facets of the Wilms’ tumour gene, WT1. Hum Mol Genet 15(Spec No 2):R196–R201CrossRefPubMedGoogle Scholar
  3. 3.
    Haber DA, Sohn RL, Buckler AJ et al (1991) Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 88(21):9618–9622. doi: 10.1073/pnas.88.21.9618 CrossRefPubMedGoogle Scholar
  4. 4.
    Pritchard-Jones K (1999) The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis. Pediatr Nephrol 13(7):620–625PubMedGoogle Scholar
  5. 5.
    Kreidberg JA (1996) Gene targeting in kidney development. Med Pediatr Oncol 27(5):445–452. doi: 10.1002/(SICI)1096-911X(199611)27:5<445::AID-MPO10>3.0.CO;2-9 CrossRefPubMedGoogle Scholar
  6. 6.
    Maurer U, Brieger J, Weidmann E et al (1997) The Wilms’ tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 25(9):945–950PubMedGoogle Scholar
  7. 7.
    Sugiyama H (2001) Wilms’ tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 73(2):177–187. doi: 10.1007/BF02981935 CrossRefPubMedGoogle Scholar
  8. 8.
    Algar EM, Khromykh T, Smith SI et al (1996) A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 12(5):1005–1014PubMedGoogle Scholar
  9. 9.
    Inoue K, Tamaki H, Ogawa H et al (1998) Wilms’ tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91(8):2969–2976PubMedGoogle Scholar
  10. 10.
    Yamagami T, Sugiyama H, Inoue K et al (1996) Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87(7):2878–2884PubMedGoogle Scholar
  11. 11.
    Xue S, Gao L, Gillmore R et al (2004) WT1-targeted immunotherapy of leukaemia. Blood Cells Mol Dis 33(3):288–290. doi: 10.1016/j.bcmd.2004.08.018 CrossRefPubMedGoogle Scholar
  12. 12.
    Keilholz U, Menssen HD, Gaiger A et al (2005) Wilms’ tumour gene 1 (WT1) in human neoplasia. Leukemia 19(8):1318–1323. doi: 10.1038/sj.leu.2403817 CrossRefPubMedGoogle Scholar
  13. 13.
    Oka Y, Tsuboi A, Oji Y et al (2008) WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20(2):211–220. doi: 10.1016/j.coi.2008.04.009 CrossRefPubMedGoogle Scholar
  14. 14.
    Cilloni D, Messa F, Carturan S et al (2004) Myelodysplastic syndromes. Ann N Y Acad Sci 1028:400–408. doi: 10.1196/annals.1322.048 CrossRefPubMedGoogle Scholar
  15. 15.
    Menssen HD, Renkl HJ, Rodeck U et al (1995) Presence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9(6):1060–1067PubMedGoogle Scholar
  16. 16.
    Miwa H, Beran M, Saunders GF (1992) Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia 6(5):405–409PubMedGoogle Scholar
  17. 17.
    Inoue K, Ogawa H, Sonoda Y et al (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89(4):1405–1412PubMedGoogle Scholar
  18. 18.
    Baird PN, Simmons PJ (1997) Expression of the Wilms’ tumor gene (WT1) in normal hemopoiesis. Exp Hematol 25(4):312–320PubMedGoogle Scholar
  19. 19.
    Inoue K, Ogawa H, Yamagami T et al (1996) Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88(6):2267–2278PubMedGoogle Scholar
  20. 20.
    Cilloni D, Saglio G (2004) WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 112(1–2):79–84. doi: 10.1159/000077562 CrossRefPubMedGoogle Scholar
  21. 21.
    Tamaki H, Mishima M, Kawakami M et al (2003) Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 78(4):349–356. doi: 10.1007/BF02983561 CrossRefPubMedGoogle Scholar
  22. 22.
    Cilloni D, Gottardi E, De Micheli D et al (2002) Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16(10):2115–2121. doi: 10.1038/sj.leu.2402675 CrossRefPubMedGoogle Scholar
  23. 23.
    Inoue K, Sugiyama H, Ogawa H et al (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84(9):3071–3079PubMedGoogle Scholar
  24. 24.
    Omran HA, Shabani M, Vossough P et al (2008) Cross-sectional monitoring of Wilms’ tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission. Leuk Lymphoma 49(2):281–290. doi: 10.1080/10428190701784706 CrossRefPubMedGoogle Scholar
  25. 25.
    Im HJ, Kong G, Lee H (1999) Expression of Wilms tumor gene (WT1) in children with acute leukemia. Pediatr Hematol Oncol 16(2):109–118. doi: 10.1080/088800199277434 CrossRefPubMedGoogle Scholar
  26. 26.
    Boublikova L, Kalinova M, Ryan J et al (2006) Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 20(2):254–263. doi: 10.1038/sj.leu.2404047 CrossRefPubMedGoogle Scholar
  27. 27.
    Bruggemann M, Raff T, Flohr T et al (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107(3):1116–1123. doi: 10.1182/blood-2005-07-2708 CrossRefPubMedGoogle Scholar
  28. 28.
    Siehl JM, Thiel E, Heufelder K et al (2003) Possible regulation of Wilms’ tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias. Br J Haematol 123(2):235–242. doi: 10.1046/j.1365-2141.2003.04622.x CrossRefPubMedGoogle Scholar
  29. 29.
    Siehl JM, Reinwald M, Heufelder K et al (2004) Expression of Wilms’ tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Ann Hematol 83(12):745–750. doi: 10.1007/s00277-004-0941-0 CrossRefPubMedGoogle Scholar
  30. 30.
    Garg M, Moore H, Tobal K et al (2003) Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 123(1):49–59. doi: 10.1046/j.1365-2141.2003.04552.x CrossRefPubMedGoogle Scholar
  31. 31.
    Menssen HD, Siehl JM, Thiel E (2002) Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol 76(2):103–109. doi: 10.1007/BF02982571 CrossRefPubMedGoogle Scholar
  32. 32.
    Chiusa L, Francia di Celle P, Campisi P et al (2006) Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia. Haematologica 91(2):270–271PubMedGoogle Scholar
  33. 33.
    Drakos E, Rassidakis GZ, Tsioli P et al (2005) Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl Immunohistochem Mol Morphol 13(2):132–137. doi: 10.1097/01.pai.0000143786.62974.66 CrossRefPubMedGoogle Scholar
  34. 34.
    Barragan E, Cervera J, Bolufer P et al (2004) Prognostic implications of Wilms’ tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 89(8):926–933PubMedGoogle Scholar
  35. 35.
    Bergmann L, Miething C, Maurer U et al (1997) High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90(3):1217–1225PubMedGoogle Scholar
  36. 36.
    Trka J, Kalinova M, Hrusak O et al (2002) Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16(7):1381–1389. doi: 10.1038/sj.leu.2402512 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Antonia Busse
    • 1
    Email author
  • Nicola Gökbuget
    • 2
  • Jan Michael Siehl
    • 1
  • Dieter Hoelzer
    • 2
  • Stefan Schwartz
    • 1
  • Anika Rietz
    • 1
  • Eckhard Thiel
    • 1
  • Ulrich Keilholz
    • 1
  1. 1.Department of Medicine IIICharité, Campus Benjamin FranklinBerlinGermany
  2. 2.Department of Medicine IIIJohann Wolfgang Goethe UniversityFrankfurt/M.Germany

Personalised recommendations